Cadrenal Therapeutics Statistics
Total Valuation
CVKD has a market cap or net worth of $27.61 million. The enterprise value is $22.04 million.
Important Dates
The next estimated earnings date is Friday, November 7, 2025, before market open.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CVKD has 2.05 million shares outstanding. The number of shares has increased by 54.78% in one year.
| Current Share Class | 2.05M |
| Shares Outstanding | 2.05M |
| Shares Change (YoY) | +54.78% |
| Shares Change (QoQ) | +6.38% |
| Owned by Insiders (%) | 25.96% |
| Owned by Institutions (%) | 7.33% |
| Float | 1.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 6.30 |
| P/TBV Ratio | 6.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.56
| Current Ratio | 3.56 |
| Quick Ratio | 3.33 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -340.31% and return on invested capital (ROIC) is -216.88%.
| Return on Equity (ROE) | -340.31% |
| Return on Assets (ROA) | -157.41% |
| Return on Invested Capital (ROIC) | -216.88% |
| Return on Capital Employed (ROCE) | -334.98% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.53M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -23.35% in the last 52 weeks. The beta is 0.99, so CVKD's price volatility has been similar to the market average.
| Beta (5Y) | 0.99 |
| 52-Week Price Change | -23.35% |
| 50-Day Moving Average | 13.44 |
| 200-Day Moving Average | 14.89 |
| Relative Strength Index (RSI) | 50.71 |
| Average Volume (20 Days) | 25,342 |
Short Selling Information
The latest short interest is 18,468, so 0.90% of the outstanding shares have been sold short.
| Short Interest | 18,468 |
| Short Previous Month | 9,933 |
| Short % of Shares Out | 0.90% |
| Short % of Float | 1.22% |
| Short Ratio (days to cover) | 0.62 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -14.40M |
| Pretax Income | -14.11M |
| Net Income | -14.11M |
| EBITDA | -14.39M |
| EBIT | -14.40M |
| Earnings Per Share (EPS) | -$8.62 |
Full Income Statement Balance Sheet
The company has $5.57 million in cash and n/a in debt, giving a net cash position of $5.57 million or $2.72 per share.
| Cash & Cash Equivalents | 5.57M |
| Total Debt | n/a |
| Net Cash | 5.57M |
| Net Cash Per Share | $2.72 |
| Equity (Book Value) | 4.30M |
| Book Value Per Share | 2.14 |
| Working Capital | 4.29M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$11.67 million and capital expenditures -$9,788, giving a free cash flow of -$11.68 million.
| Operating Cash Flow | -11.67M |
| Capital Expenditures | -9,788 |
| Free Cash Flow | -11.68M |
| FCF Per Share | -$5.70 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CVKD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -54.78% |
| Shareholder Yield | -54.78% |
| Earnings Yield | -51.09% |
| FCF Yield | -42.29% |
Analyst Forecast
The average price target for CVKD is $32.00, which is 137.21% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $32.00 |
| Price Target Difference | 137.21% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -22.18% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 20, 2024. It was a reverse split with a ratio of 1:15.
| Last Split Date | Aug 20, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |